scholarly journals The effectiveness and safety of topical β‐receptor blocker in treating superficial infantile haemangiomas: A meta‐analysis including 20 studies

2020 ◽  
Vol 86 (2) ◽  
pp. 199-209 ◽  
Author(s):  
Zhenying Lin ◽  
Baoxin Zhang ◽  
Zhongjing Yu ◽  
Huanyuan Li
Keyword(s):  
Meta Analysis ◽  
Receptor Blocker ◽  
Β Receptor ◽  
Infantile Haemangiomas

β-Receptor Blocker Withdrawal. A Preoperative Problem in General Surgery?

1982 ◽  
Vol 26 ◽  
pp. 32-37 ◽  
Author(s):  
J. Pontén ◽  
B. Biber ◽  
T. Bjurö ◽  
B-Å. Henriksson ◽  
Å. Hjalmarson
Keyword(s):  
General Surgery ◽  
Receptor Blocker ◽  
Β Receptor

scholarly journals Biased Safety Reporting in Blinded Randomized Clinical Trials: Meta-Analysis of Angiotensin Receptor Blocker Trials

PLoS ONE ◽  
2013 ◽  
Vol 8 (9) ◽  
pp. e75027 ◽  
Author(s):  
Nobuyoshi Takabayashi ◽  
Hisashi Urushihara ◽  
Koji Kawakami
Keyword(s):  
Clinical Trials ◽  
Angiotensin Receptor Blocker ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Safety Reporting

Treatment of Ventricular Tachycardia Storm

2011 ◽  
Vol 140 ◽  
pp. 244-247
Author(s):  
Zhao Heng Lin
Keyword(s):  
Ventricular Tachycardia ◽  
Ventricular Fibrillation ◽  
Intravenous Administration ◽  
Sinus Bradycardia ◽  
Low Energy ◽  
Receptor Blocker ◽  
Control Group ◽  
Significant Difference ◽  
Electrical Defibrillation ◽  
Β Receptor

OBJECTIVE: To investigate the clinical efficacy and safety of low-energy direct current defibrillation combined with intravenous application of β-receptor blocker in the treatment of ventricular tachycardia storm (VTS). METHODS: A total of 59 patients with VTS were randomly divided into two groups. In the control group (n = 31), intravenous administration of Lidocaine or Amiodarone and routine electrical defibrillation were performed. In the esmolol group (n = 28), intravenous administration of esmolol and low-energy electrical defibrillation were performed in addition to the same drug treatment as the control group.RESULTS: The success rate of terminating recurrent ventricular tachycardia or ventricular fibrillation was significantly higher in the esmolol group than in the control group (89.71% vs. 39.89%, P < 0.05). The necessary discharge times and average discharge energy to terminate ventricular tachycardia or ventricular fibrillation were significantly decreased in the esmolol group compared with control (5.69 ± 1.34 times vs. 8.63 ± 3.79 times, 95.32 ± 13.21J vs. 185.39 ± 25.63J, both P < 0.05). There was no significant difference in the incidence of hypotension (45.16% vs. 39.29%), sinus bradycardia (3.23% vs. 3.57%), and junctional/ventricular escape (38.71% vs. 39.29%) between the esmolol and control groups (all P > 0.05). The mortality was significantly lower in the esmolol group than in the control group (21.43%, 6/28 vs. 77.42%, 24/31, P < 0.01).CONCLUSION: Compared with conventional treatment, intravenous administration of a β-receptor blocker combined with low-energy electrical defibrillation could be a safe and effective therapy to treat VTS.

Compared Incidence of First Myocardial Infarction in Hypertensive Patients under Treatment Containing Propranolol or excluding β-Receptor Blockade

1976 ◽  
Vol 51 (s3) ◽  
pp. 509s-511s ◽  
Author(s):  
I. McD. G. Stewart
Keyword(s):  
Myocardial Infarction ◽  
Term Treatment ◽  
Receptor Blocker ◽  
Receptor Blockade ◽  
Hypertensive Patients ◽  
Long Term Treatment ◽  
Significant Difference ◽  
Group A ◽  
Β Receptor

1. After some exclusions, 169 severe uncomplicated essential hypertensive patients presenting consecutively were divided into two groups according to their treatment. Of these, 121 had been given long-term treatment containing propranolol (PC group) and forty-eight had been treated with hypotensive agents excluding any β-receptor-blocker group, the non-β-receptor-blocker (NBB) group. 2. There were no significant differences in myocardial infarction risk factors between the two groups. 3. After a mean follow-up of 5·25 years, nine of the 121 subjects (7·5%) in the PC group had suffered first infarctions and fifteen of the forty-eight subjects (31%) in the NBB group, a significant difference (P < 0·01). 4. It was concluded that the presence of propranolol had prevented more or caused fewer infarctions, perhaps a combination of both, than had the older hypotensive agents unsupported by β-receptor blockade.

scholarly journals NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC

2017 ◽  
Vol 8 (2) ◽  
pp. e2634-e2634 ◽  
Author(s):  
Yuan Cao ◽  
Rahul Agarwal ◽  
Francesco Dituri ◽  
Luigi Lupo ◽  
Paolo Trerotoli ◽  
...  
Keyword(s):  
Transcriptome Profiling ◽  
Receptor Blocker ◽  
Companion Diagnostics ◽  
Β Receptor

Meta-analysis of transforming growth factor β receptor I 6A/9A gene polymorphism and breast cancer risk: the picture remains murky

Biomarkers ◽  
2015 ◽  
Vol 20 (6-7) ◽  
pp. 487-494
Author(s):  
Chao Ou ◽  
Hang Li ◽  
Jiang-Hua Liu ◽  
Gregor P. C. Drummen ◽  
Bo Zhu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Gene Polymorphism ◽  
Transforming Growth Factor ◽  
Meta Analysis ◽  
Transforming Growth Factor Β ◽  
Β Receptor
Sign in / Sign up

Export Citation Format

Share Document